XOMA Limited (NASDAQ:XOMA)

CAPS Rating: 2 out of 5

A biopharmaceutical company that discovers, develops and manufactures antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer and infectious diseases.

Results 1 - 20 of 67 : 1 2 3 4 Next »

Recs

0
Member Avatar TMFBiologyFool (97.30) Submitted: 3/6/2014 7:03:57 PM : Outperform Start Price: $6.59 XOMA Score: -43.33

Knockdown after EOA data looks like a decent entry point.

Recs

0
Member Avatar Crystalball (95.44) Submitted: 3/6/2014 11:28:21 AM : Outperform Start Price: $6.82 XOMA Score: -45.66

Gevokuzimab could still be used on 10 other indications. Sell off way overdone.

Recs

0
Member Avatar outinthesnow (52.34) Submitted: 12/27/2013 1:02:10 AM : Outperform Start Price: $7.32 XOMA Score: -52.14

Old favorite

Recs

0
Member Avatar 78taxs (< 20) Submitted: 11/1/2013 11:24:52 PM : Outperform Start Price: $4.23 XOMA Score: -16.36

med that we need .

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 5:31:32 PM : Underperform Start Price: $4.50 XOMA Score: +28.93

Short. Biotech that sells stock.

Recs

0
Member Avatar savvyhelper (< 20) Submitted: 7/13/2013 12:40:42 PM : Outperform Start Price: $4.70 XOMA Score: -31.74

research is on the move and hope fully cures

Recs

1
Member Avatar usubanas (99.39) Submitted: 11/20/2012 11:49:34 PM : Outperform Start Price: $3.04 XOMA Score: -6.64

Nov 7 CC: top line data from EYEGUARD-A study at the end of 2013.
I can wait a year.

Recs

0
Member Avatar RSue (91.85) Submitted: 4/28/2012 3:18:31 AM : Outperform Start Price: $2.48 XOMA Score: +17.63

Quality scientific organization with deep pipeline in area of breakthrough novel antibody therapeutics under direction and leadership of deeply experienced Senior Vice-President of Research and Development/Chief Medical Officer Dr. Paul Rubin.

Recs

0
Member Avatar measured (74.69) Submitted: 4/24/2012 4:50:40 PM : Outperform Start Price: $2.85 XOMA Score: -0.93

Need to have patience.A multibagger

Recs

6
Member Avatar zzlangerhans (99.67) Submitted: 3/7/2012 11:11:08 PM : Underperform Start Price: $1.89 XOMA Score: -66.69

Investing in a Xoma, you know
You know, it's dubious

Investing in a Xoma, you know
You know, it's really dubious

There were times when I could have invested there
But you know, it was a good thing I didn't buy a share

No! Behcet's won't give cash flow!

Do you really think they'll pull through?
I don't really think they'll pull through

Investing in a Xoma, you know
You know, it's dubious

X,O,M,A,0,5,2 baby goodbye

There were times when I could have invested there
But you know, it was a good thing I didn't buy a share

Recs

0
Member Avatar jimscottage11 (< 20) Submitted: 12/19/2011 7:00:59 AM : Outperform Start Price: $1.18 XOMA Score: +179.85

New 52wk low on fri 16th 2011. could bounce

Recs

0
Member Avatar danienov (< 20) Submitted: 12/9/2011 3:13:29 PM : Outperform Start Price: $1.46 XOMA Score: +119.42

052

Recs

0
Member Avatar p1a5244 (57.99) Submitted: 9/18/2011 11:20:44 PM : Outperform Start Price: $2.13 XOMA Score: +24.11

9/18/11 Options Predictor Rank #33. P/C Ratio 0.075 and Call Sizzle 3.383.

Recs

0
Member Avatar rwpaules (92.79) Submitted: 6/20/2011 12:15:41 PM : Underperform Start Price: $2.30 XOMA Score: -20.73

Poster child for R&D futility. Betting on them could be lucrative. Betting against them could be reasonable.

Recs

0
Member Avatar SCmaverick96 (< 20) Submitted: 4/7/2011 8:33:29 PM : Outperform Start Price: $3.47 XOMA Score: -31.23

I bought this stock around $5/share. Yes, I did take a huge blow from the bad research data about diabetes but I still believe I got a deal because cardiovascular is where it's at. I'm a nurse and that is what leads our nation in death tolls. The research is there, they just need to make it work. I know that's a big "IF" but I'm willing to hold on. I will buy more shares as soon as I can. I'm trying to keep my faith in the XOMA team to give that huge blockbuster drug so I can retire at 30.

Recs

0
Member Avatar hrairk (< 20) Submitted: 3/22/2011 10:25:16 PM : Underperform Start Price: $3.32 XOMA Score: +31.67

Their "flagship" product just sank.

Recs

0
Member Avatar dangank (< 20) Submitted: 2/16/2011 10:30:29 AM : Outperform Start Price: $4.94 XOMA Score: -65.71

The science seems to be sound, but one has the sense that no one, not even management really knows.

Recs

0
Member Avatar prior601 (< 20) Submitted: 2/9/2011 7:25:49 AM : Outperform Start Price: $5.26 XOMA Score: -72.65

Set to blow!

Recs

0
Member Avatar graniteguys (54.37) Submitted: 1/5/2011 2:27:05 PM : Outperform Start Price: $6.75 XOMA Score: -95.10

Bought before reverse split
Hope make money back and little gain

Recs

0
Member Avatar dahabnick (< 20) Submitted: 12/28/2010 4:30:50 PM : Outperform Start Price: $4.82 XOMA Score: -73.03

This is one of those single disease, solution focused companies. I believe diabetes is there game. Either they succeed or they don't. It will take time before there product can climb through the FDA approval jungle. Thats why Isay , at least 2 years. Anticipation until then will make it rise faster than others.

Results 1 - 20 of 67 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement